Abdel Aziz Ashraf O.

Dr. Ashraf O. Abdel Aziz is a prominent academic and clinician in the field of hepatology and oncology, affiliated with leading Egyptian institutions including Cairo University, the National Cancer Institute, and the National Research Centre. He serves in the Faculty of Medicine at Cairo University, contributing to both clinical practice and advanced research in liver diseases and cancer.

His research interests center on hepatocellular carcinoma (HCC), hepatitis C virus (HCV), and the application of novel therapies such as immune checkpoint inhibitors and sofosbuvir-based antiviral regimens. He has pioneered the use of data mining techniques to predict HCC risk in Egyptian populations, addressing a major public health challenge. His work bridges clinical medicine with computational and molecular approaches to improve patient outcomes.

The most recent publications highlight a strong trend in translational hepatology, focusing on real-world treatment efficacy, viral recurrence post-transplant, and genetic factors in disease progression. His research is deeply rooted in the Egyptian healthcare context, particularly concerning HCV genotype 4 and post-liver transplant management.

Dr. Abdel Aziz has secured research funding and collaboration from prestigious sponsors including the National Institutes of Health and the Bill & Melinda Gates Foundation, underscoring his international academic influence. While no formal advising roles are listed, his extensive co-authorship network suggests active mentorship and team-based research leadership.

His work is conducted within multidisciplinary teams at major medical centers such as the National Cancer Institute and Dar Al Fouad Hospital, where clinical and research units collaborate to advance liver disease treatment and cancer care in Egypt.